NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Viking manufacturing agreement removes key overhang, says Morgan Stanley
After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...
Viking Therapeutics Is Ready For A Standalone Future
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
The Copenhagen Post58m
Demokraatit wins Greenlandic election, here are the reactions
Danish Prime Minister Mette Frederiksen acknowledged the result, stating:  “Election Day in Greenland yesterday was a joyful day and a celebration of democracy. I would like to congratulate ...